MLYS
Mineralys Therapeutics Inc

566
Mkt Cap
$1.98B
Volume
2.89M
52W High
$47.65
52W Low
$10.44
PE Ratio
-10.12
MLYS Fundamentals
Price
$24.07
Prev Close
$23.28
Open
$23.12
50D MA
$29.55
Beta
0.98
Avg. Volume
1.13M
EPS (Annual)
-$2.29
P/B
3.03
Rev/Employee
$0.00
$1,798.61
Loading...
Loading...
News
all
press releases
Research Analysts Issue Forecasts for MLYS Q1 Earnings
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) - Equities researchers at HC Wainwright lifted their Q1 2026 earnings per share estimates for shares of Mineralys Therapeutics in a note...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
HC Wainwright Has Positive Outlook of MLYS FY2029 Earnings
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) - Stock analysts at HC Wainwright increased their FY2029 earnings estimates for Mineralys Therapeutics in a research report issued to clients...
MarketBeat·4d ago
News Placeholder
Mineralys Therapeutics (NASDAQ:MLYS) Insider David Malcom Rodman Sells 6,348 Shares
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 6,348 shares of the business's stock in a transaction on Thursday, March 12th. The shares were sold at an...
MarketBeat·5d ago
News Placeholder
Holocene Advisors LP Buys Shares of 1,205,377 Mineralys Therapeutics, Inc. $MLYS
Holocene Advisors LP purchased a new position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) during the third quarter, according to the company in its most recent Form 13F filing with...
MarketBeat·5d ago
News Placeholder
David Malcom Rodman Sells 6,348 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 6,348 shares of the company's stock in a transaction dated Thursday, March 12th. The stock was sold at an...
MarketBeat·5d ago
News Placeholder
David Malcom Rodman Sells 14,058 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) insider David Malcom Rodman sold 14,058 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was sold at an...
MarketBeat·5d ago
News Placeholder
HighVista Strategies LLC Boosts Position in Mineralys Therapeutics, Inc. $MLYS
HighVista Strategies LLC raised its position in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 39.8% during the third quarter, according to its most recent disclosure with the...
MarketBeat·5d ago
News Placeholder
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Consensus Rating of "Moderate Buy" from Brokerages
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) has been given a consensus rating of "Moderate Buy" by the eight analysts that are presently covering the company, Marketbeat reports. One...
MarketBeat·6d ago
News Placeholder
Boothbay Fund Management LLC Increases Position in Mineralys Therapeutics, Inc. $MLYS
Boothbay Fund Management LLC boosted its position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 15.4% in the third quarter, according to its most recent disclosure with the...
MarketBeat·7d ago
News Placeholder
Mineralys Therapeutics, Inc. $MLYS Shares Sold by 22NW LP
22NW LP reduced its stake in shares of Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) by 36.0% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC...
MarketBeat·7d ago
<
1
2
...
>

Latest MLYS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.